Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Case ReportClinical Studies

Teratogenic Effect of Radotinib: Case Report

JUYOUNG CHEON, JUNG WHAN AHN, KYUNG MIN PARK, GUISERA LEE and YUN SUNG JO
Anticancer Research December 2016, 36 (12) 6599-6601;
JUYOUNG CHEON
Department of Obstetrics and Gynecology, College of Medicine, St. Vincent's Hospital, The Catholic University of Korea, Seoul, Republic of Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JUNG WHAN AHN
Department of Obstetrics and Gynecology, College of Medicine, St. Vincent's Hospital, The Catholic University of Korea, Seoul, Republic of Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KYUNG MIN PARK
Department of Obstetrics and Gynecology, College of Medicine, St. Vincent's Hospital, The Catholic University of Korea, Seoul, Republic of Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
GUISERA LEE
Department of Obstetrics and Gynecology, College of Medicine, St. Vincent's Hospital, The Catholic University of Korea, Seoul, Republic of Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YUN SUNG JO
Department of Obstetrics and Gynecology, College of Medicine, St. Vincent's Hospital, The Catholic University of Korea, Seoul, Republic of Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: eggs76@catholic.ac.kr
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

This article has a correction. Please see:

  • Retraction - February 01, 2017

Abstract

Background: Simultaneous presentation of pregnancy and chronic myeloid leukemia (CML) is rare. Tyrosine kinase inhibitors (TKIs) are rarely used in pregnancy. There is almost no information on the effect of recently developed TKIs on the fetus. Case Report: A 22-year-old woman became pregnant while using radotinib, a novel TKI for CML. She was concerned about the possible teratogenic effect of radotinib; hence the first pregnancy was terminated. The patient underwent full-term delivery at the second pregnancy. The infant had facial deformity and congenital laryngomalacia. Conclusion: We witnessed structural abnormality when the patient used radotinib during the first trimester of pregnancy. When radotinib is prescribed for women of childbearing age, thorough education about contraception is necessary.

  • Chronic myeloid leukemia
  • radotinib
  • teratogen
  • tyrosine kinase inhibitor
  • pregnancy
  • malformation
  • case report

Chronic myeloid leukemia (CML) often occurs in elderly patients (1). Simultaneous presentation of pregnancy and CML is rare (2). Because of their excellent therapeutic effect, tyrosine kinase inhibitors (TKIs) have been used as standard treatment for CML (3). However, there is controversy regarding the effectiveness of TKIs and uncertainty about the effects on the fetus due to the lack of reports of their use during pregnancy. Although imatinib is a TKI that has been used since 1998, little information is available about its effect on the fetus during pregnancy. Radotinib, a novel TKI, is a drug used for CML. It is under preclinical trial. Here we report a case of a woman pregnant twice while taking raditinib who gave birth to a baby with congenital malformation.

Case Report

A 19-year-old patient, gravida 1 para 0, was referred for amenorrhea for 7 weeks 6 days. The patient had been diagnosed with CML 1 year earlier and had been taking 200 mg radotinib twice daily orally for 1 year. Six months before referral, in chronic phase, a complete cytogenic response was achieved. Normally, the patient had regular menstruation. The result of urine human chorionic gonadotropin (HCG) test was positive and the ultrasound examination showed that G-sac was 1.26 cm. The fetal pole measured 2.4 mm (5 weeks 5 days of gestation). Fetal heart beat was 105 bpm/min. She was concerned about the teratogenic effect of radotinib; hence she decided to have a termination of pregnancy.

The patient visited the hospital again 3 years later at 22 years old for 11 weeks and 4 days of amenorrhea. Usually she had regular menstruation. The patient had been taking 300 mg of radotinib twice daily orally at that time but had stopped taking radotinib after a urine HCG test was confirmed to be positive 12 days prior to this consultation. Ultrasound examination revealed a single intrauterine pregnancy of 12 weeks and 3 days of gestation. It was conjecturable that she had taken radotinib until 10 weeks and 5 days of gestation. The patient chose to continue the pregnancy and stopped taking radotinib. Blood analysis revealed the following: white blood cell count of 5,490 cells/mm3, hemoglobin level of 9.4 g/dl, and platelet count of 64,000 cells/mm3. Her renal and liver functions were normal. The pregnant woman had regular antenatal checkups; there was nothing significant to report. She had a complete blood count every month. There was no medical opinion of CML deterioration.

At the 39th week and 6th day, the patient gave birth to a baby girl (3.330 kg) vaginally. The Apgar score of the infant was 8 at 1 min and 9 at 5 min. Examination revealed both low-set ears and absence of angle between the forehead and nose (Figure 1A). No other external deformation was found. However, while the patient was breastfeeding, cyanosis and around 70% of desaturation occurred in addition to cow-like crying of the infant. Chest x-ray revealed haziness on both lower lungs. Rib deformity was suspected (Figure 1B). Chest computed tomography showed atelectasis on both lower lungs (Figure 1C). The rib cage was found to be normal (Figure 1D). On echocardiogram, there was nothing significant to report. Laryngoscopy revealed laryngomalacia. The epiglottis was omega-shaped and arytenoid collapsed during inspiration. On placental pathological examination, there was increased intervillous fibrin deposition without any other abnormal findings. The infant's desaturation and atelectasis had improved by the time she was 10 days old. Therefore, she was released from the hospital. There were no other abnormal findings during the 3-month follow-up visit.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

The infant born to a woman who became pregnant while taking radotinib. A: The infant had low-set ears and absence of angle between the forehead and nose. B: Chest X-ray showing haziness in the lower lung field. Rib deformity was suspected. C. Chest computed tomography showing atelectasis of both lungs. D: 3D Chest computed tomography showing the rib cage to be normal.

Discussion

CML comprises approximately 15% of adult leukemia (4). The occurrence rate ranges from 0.6 to two cases out of 100,000 (1). Men are more likely to develop CML (1). The median age at diagnosis is 64 years (1). CML in pregnancy is a rare condition (one in 100,000) (2). Since molecular-targeted therapy with TKIs has been used for treatment of CML, the cure rate of CML has been dramatically improved. Currently, TKIs are the standard treatment for CML (3). Nevertheless, imatinib can increase abortion, congenital malformation, such as exencephaly, encephalocele, and chemical bone hypoplasia in animal studies (5). Although the effect of TKIs on human fetal development remains unclear, several case reports have shown good outcomes. However, one study, in which imatinib treatment was performed, reported that 18 (14.4%) out of 125 pregnant women experienced spontaneous abortion, while babies born to 12 (9.6%) pregnant women had congenital malformation(6). Therefore, a potent teratogenic effect of TKIs should be carefully considered. In addition, newer TKIs, such as dasatinib and nilotinib, have been approved by the US and are available on the market. There are insufficient data about the effect of such medicines on fetal development. Accordingly, whether TKIs should be used during pregnancy is a difficult decision. The decision should be made by the patients, their families, obstetricians, and hematologists together after careful consideration depending on each patient's situation.

We witnessed structural abnormality when the patient used radotinib during the first trimester. To the best of our knowledge, this is the first report of an association between radotinib and pregnancy. Thus, TKIs, especially newer TKIs, should be avoided during pregnancy because their safety is not guaranteed. When it is used on women of childbearing age, thorough education about contraception is necessary.

  • Received September 28, 2016.
  • Revision received October 19, 2016.
  • Accepted October 20, 2016.
  • Copyright© 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved

References

  1. ↵
    1. National Cancer Institute
    : Previous Version: SEER Cancer Statistics Review, 1975-2010. Updated June 14, 2013. Available at: http://seer.cancer.gov/csr/1975_2010/ (Accessed March 8, 2016).
  2. ↵
    1. Coller B,
    2. Kipps T,
    3. Seligsohn U,
    4. Beutler E,
    5. Lichtman M
    1. Lichtman M,
    2. Liesveld J
    : Acute myelogenous leukemia. In: Williams Hematology. Sixth Edition. Coller B, Kipps T, Seligsohn U, Beutler E, Lichtman M (eds.) New York: McGraw-Hill: pp. 1047-1084, 2001.
  3. ↵
    1. Hasford J,
    2. Pfirrmann M,
    3. Hochhaus A
    : How long will chronic myeloid leukemia patients treated with imatinib mesylate live? Leukemia 19(4): 497-499, 2005.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Weisberg E,
    2. Manley P,
    3. Mestan J,
    4. Cowan-Jacob S,
    5. Ray A,
    6. Griffin JD
    : AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer 94(12): 1765-1769, 2006.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Russell MA,
    2. Carpenter MW,
    3. Akhtar MS,
    4. Lagattuta TF,
    5. Egorin MJ
    : Imatinib mesylate and metabolite concentrations in maternal blood, umbilical cord blood, placenta and breast milk. J Perinatol 27(4): 241-243, 2007.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Pye SM,
    2. Cortes J,
    3. Ault P,
    4. Hatfield A,
    5. Kantarjian H,
    6. Pilot R,
    7. Rosti G,
    8. Apperley JF
    : The effects of imatinib on pregnancy outcome. Blood 111(12): 5505-5508, 2008.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

Anticancer Research: 36 (12)
Anticancer Research
Vol. 36, Issue 12
December 2016
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Teratogenic Effect of Radotinib: Case Report
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
2 + 9 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Teratogenic Effect of Radotinib: Case Report
JUYOUNG CHEON, JUNG WHAN AHN, KYUNG MIN PARK, GUISERA LEE, YUN SUNG JO
Anticancer Research Dec 2016, 36 (12) 6599-6601;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Teratogenic Effect of Radotinib: Case Report
JUYOUNG CHEON, JUNG WHAN AHN, KYUNG MIN PARK, GUISERA LEE, YUN SUNG JO
Anticancer Research Dec 2016, 36 (12) 6599-6601;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Case Report
    • Discussion
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • Retraction
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Tumor Budding Grade and T Stage as Recurrence Predictors of High-risk Stage II Colorectal Cancer
  • Pathologic Complete Response (pCR) in Patient With Myxofibrosarcoma Who Underwent Neoadjuvant Radiation Concurrent to Complementary and Alternative Medicine
  • Machine Learning Model to Guide Empirical Antimicrobial Therapy in Febrile Neutropenic Patients With Hematologic Malignancies
Show more Clinical Studies

Similar Articles

Keywords

  • chronic myeloid leukemia
  • radotinib
  • teratogen
  • tyrosine kinase inhibitor
  • pregnancy
  • malformation
  • Case report
Anticancer Research

© 2025 Anticancer Research

Powered by HighWire